Australian medical technology company Next Science Limited listed on the Australian Stock Exchange (ASX) today following a successful $35 million initial public offer (IPO) in March. The company will now be trading under ASX ticker code NXS.

Under its IPO, Next Science offered 35,000,010 shares at A$1.00 per share and received strong interest from institutional and retail investors and the offer closed oversubscribed. The IPO shares have now been allotted to over 1,500 shareholders, including a number of well-regarded institutional investors.

Millions of people worldwide are affected by biofilm-based tissue and device-caused infections, such as chronic wounds, middle-ear, sinusitis, implant- and catheter-associated infections, each year.

Next Science’s Xbio platform works by destroying biofilms – surface films formed by bacteria and fungi that shields them from conventional methods of eradication, promoting antibiotic resistance.  Next Science’s proprietary Xbio technology is a non-toxic technology with proven efficacy in eradicating biofilm and biofilm protected bacteria and fungi.

Judith Mitchell, Next Science’s CEO, said, “Next Science is an emerging Australian medical technology company and it has an important global job to do to provide effective solutions to treat and keep people safe from bacterial and fungal infections – these infections not only have a significant cost to our health systems but have a real human cost for patients suffering from infections, too.”

Sefiani worked closely with the management team in the months leading up to the IPO, securing extensive supportive media coverage across business media in Australia. Sefiani also produced a video series with the Chairman, Chief Executive Officer and Chief Financial Officer to help educate investors about the company, its robust technology and market growth opportunities.